# Alto Neuroscience, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Alto Neuroscience, Inc.). ## Overview Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on psychiatry and other central nervous system disorders. Founded in 2019 and based in Mountain View, California, it is building a Precision Psychiatry Platform that uses neurobiology and data science to identify biomarkers and match patients to treatments more likely to work for them. The company’s pipeline includes seven clinical-stage assets across major depressive disorder, bipolar depression, treatment-resistant depression, schizophrenia, and Parkinson’s disease. Alto is still in development mode, with no commercial products and no internal manufacturing footprint, and relies on third-party partners for clinical supply and future commercialization support. ## Products & services • Precision Psychiatry Platform for biomarker-driven psychiatry • ALTO-100 for major depressive disorder • ALTO-101 for cognitive impairment associated with schizophrenia • ALTO-202 for major depressive disorder • ALTO-203 for neuropsychiatric indications • ALTO-207 for treatment-resistant depression • ALTO-208 for Parkinson’s disease - **Precision psychiatry platform** (0%) — Proprietary neurobiology and data-science tools used to identify biomarkers and stratify patients for clinical development. - **Clinical-stage CNS drug candidates** (100%) — Investigational therapies targeting depression, schizophrenia, and Parkinson’s disease across multiple mechanisms. - Precision Psychiatry Platform for biomarker-driven psychiatry - ALTO-100 for major depressive disorder - ALTO-101 for cognitive impairment associated with schizophrenia - ALTO-202 for major depressive disorder - ALTO-203 for neuropsychiatric indications - ALTO-207 for treatment-resistant depression - ALTO-208 for Parkinson’s disease ## Customers Alto does not currently sell commercial products, so its near-term customers are primarily clinical trial participants, investigators, and research sites that support development of its drug candidates. If approved, the company expects to sell into psychiatry and neurology treatment markets, where physicians prescribe therapies for patients with major depressive disorder, treatment-resistant depression, bipolar depression, schizophrenia, and Parkinson’s disease. The company’s precision approach is designed to appeal to clinicians and payers seeking better response rates in heterogeneous patient populations. Alto also expects to work with commercialization partners outside the United States, suggesting future customers may include regional pharmaceutical partners and distributors. - **Clinical trial participants** (primary) — Patients enrolled in Alto’s studies for MDD, schizophrenia, TRD, bipolar depression, and Parkinson’s disease to generate efficacy and biomarker data. - **Clinical investigators and research sites** (primary) — Hospitals, clinics, and trial sites that administer protocols and collect data needed to advance the pipeline. - **Psychiatrists and neurologists** (secondary) — Future prescribers who would use Alto’s approved products if development succeeds, especially in hard-to-treat CNS disorders. - **Commercial partners** (emerging) — Potential licensing or commercialization partners, especially outside the United States, that could help launch approved products. - Clinical trial patients enrolled in psychiatry and CNS studies - Investigators and clinical sites running Alto-sponsored trials - Psychiatrists treating major depressive disorder and TRD - Neurologists treating Parkinson’s disease and related symptoms - Potential pharma partners for ex-U.S. commercialization ## Geography Alto is headquartered in Mountain View, California and is incorporated in Delaware, with operations centered in the United States. The company’s current development work is primarily U.S.-based, including clinical operations, management, and oversight of third-party manufacturers and CROs. Management has said it may pursue commercialization partnerships outside the United States, which would broaden geographic exposure if any product is approved. No country-level revenue disclosure is available because the company has not commercialized products. - Headquartered in Mountain View, California - Incorporated in Delaware and managed from the United States - Clinical development and oversight are primarily U.S.-based - Relies on third-party CMOs and CROs rather than owned facilities - May seek ex-U.S. commercialization partners after approval ## Strategy Alto’s strategy is to build a differentiated psychiatry pipeline around biomarker-based patient stratification rather than the traditional all-comer model. The company is prioritizing clinical development of its most advanced assets, including ALTO-207, while also advancing ALTO-101, ALTO-202, and ALTO-208 into later-stage planning and testing. It is trying to preserve capital by reducing headcount and re-deploying savings toward the highest-priority programs. Alto also intends to keep commercialization flexible, using internal capabilities in the U.S. and opportunistic partnerships abroad if products reach approval. - **Advance the clinical pipeline** (short-term) — The company has no commercial revenue, so value creation depends on generating positive clinical data and moving assets toward regulatory milestones. - **Focus capital on highest-priority programs** (short-term) — As a clinical-stage company with limited resources, Alto needs to concentrate spending on programs with the best probability of value creation. - **Build a differentiated precision psychiatry franchise** (medium-term) — Biomarker-based patient selection is intended to improve clinical success rates and create a competitive moat versus untargeted CNS drug development. - **Prepare for future commercialization** (medium-term) — If products are approved, Alto will need a scalable launch model and may need partners outside the U.S. to reach global markets efficiently. - Use biomarker-driven precision psychiatry to improve response rates - Advance a multi-asset CNS pipeline across depression, schizophrenia, and Parkinson’s - Prioritize ALTO-207 and other most advanced programs - Preserve cash through operating efficiency and headcount reduction - Retain optionality for ex-U.S. commercialization partnerships ## Risks Alto faces the core risks of a clinical-stage biopharmaceutical company: no approved products, no commercial revenue, and a high probability that one or more programs may fail in development. Its precision psychiatry strategy depends on identifying biomarkers that translate into better outcomes, but clinical results may not replicate across heterogeneous CNS populations. The company also relies heavily on CROs, CMOs, and other third parties, so trial execution, supply continuity, and data integrity are operationally critical. In addition, competition in neuropsychiatry is intense, and larger companies may have more capital, broader development capabilities, and stronger commercialization infrastructure. Cybersecurity, intellectual property, and funding needs are also material because Alto must protect sensitive clinical data, defend its asset rights, and raise substantial additional capital over time. - **Clinical development failure** [critical] — The company’s value depends on positive data from seven clinical-stage assets, and any trial setback could materially reduce pipeline value. - **Funding and dilution risk** [high] — Alto expects to need substantial additional capital to fund operations and clinical development beyond its current runway. - **Third-party trial and manufacturing dependence** [high] — The company relies on CROs and CMOs for clinical execution and supply, so delays or quality issues can slow development. - **Competitive pressure in CNS drug development** [high] — Larger biopharma and biotech competitors may reach approval faster or commercialize more effectively in psychiatry and neuroscience. - **Cybersecurity and data privacy** [medium] — Clinical and biomarker data are sensitive, and breaches or system disruptions could impair trials and damage trust. - Clinical failure risk across multiple CNS programs - No commercial products or revenue base - Dependence on biomarkers that may not predict response reliably - Third-party CRO and CMO execution risk - Intense competition from better-capitalized pharma and biotech peers - Ongoing need for external financing - Cybersecurity and data integrity risk in clinical operations - Intellectual property and licensing obligations ## Accounting As a clinical-stage biotech, Alto’s reported results are dominated by research and development accruals, milestone payments, and stock-based compensation rather than product revenue. A key judgment area is accrued R&D expense, where management estimates services performed by sites, CROs, and vendors before invoices are received; this can materially affect quarterly expense recognition. The company also has license and asset purchase agreements that may require future milestone or royalty payments, so contingent obligations and related liabilities need careful monitoring. Because Alto is still pre-commercial, there is no revenue recognition complexity from product sales yet, but investors should expect significant quarter-to-quarter volatility in operating expenses as trial timing shifts and program priorities change. - **Accrued research and development expenses** — Can move quarterly R&D expense and accrued liabilities materially - **Milestone and royalty obligations** — Can create contingent liabilities and cash outflows - **Stock-based compensation** — Affects G&A and R&D expense - **Clinical program timing and expense volatility** — Makes period-to-period comparisons less stable - Accrued research and development expenses depend on estimates of unbilled trial services - Milestone and royalty obligations under license agreements can create contingent liabilities - Stock-based compensation affects operating expense and can be sensitive to valuation assumptions - Quarterly R&D spending can swing with trial timing, enrollment, and program prioritization - No product revenue yet, so future revenue recognition will only matter after approval --- *Last updated: 2026-08-11T04:46:20.208015+00:00*